Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
3.020
+0.040 (1.34%)
Jul 29, 2026, 3:04 PM CST
SHE:300267 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,060 | 1,166 | 1,140 | 1,783 | 1,871 | 2,235 |
Revenue Growth | -12.96% | 2.30% | -36.09% | -4.67% | -16.32% | -6.17% |
Gross Profit Gross Profit Growth | 238.95 | 261.03 | 289.86 | 281.73 | 410.79 | 319.44 |
Operating Income Operating Income Growth | -54.16 | -34.83 | -90.18 | -183.08 | -10.65 | -150.49 |
Net Income Net Income Growth | -394.82 | -379.82 | -373.37 | -195.32 | 45.94 | -791.2 |
Earnings Per Share EPS Growth | -0.19 | -0.18 | -0.18 | -0.09 | 0.02 | -0.38 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Industry Pharmaceutical Industry Growth | 919.26 | 1,107 | 1,733 | 1,784 | 2,221 |
New Energy Industry New Energy Industry Growth | 213.28 | 9.99 | 30.11 | - | - |
Others Others Growth | 33.22 | 22.31 | 19.79 | 86.17 | 14.08 |
Total Total Growth | 1,166 | 1,140 | 1,783 | 1,871 | 2,235 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,067 | 987.4 | 818.54 | 744.47 | 878.79 | 761.56 |
Total Debt Total Debt Growth | 717.05 | 588.03 | 509.27 | 345.21 | 403.33 | 252.04 |
Net Cash (Debt) Net Cash Growth | 349.79 | 399.38 | 309.27 | 399.25 | 475.46 | 509.53 |
Net Cash Growth | 23.16% | 29.13% | -22.54% | -16.03% | -6.69% | -38.28% |
Net Cash Per Share Net Cash Per Share Growth | 0.17 | 0.19 | 0.15 | 0.19 | 0.23 | 0.25 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 251.92 | 257.68 | 166.69 | 148.42 | 281.02 | 92.68 |
Capital Expenditures CapEx Growth | -169.14 | -163.98 | -195.6 | -238.19 | -173.49 | -349.33 |
Free Cash Flow Free Cash Flow Growth | 82.78 | 93.7 | -28.91 | -89.77 | 107.53 | -256.65 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 22.55% | 22.39% | 25.44% | 15.80% | 21.96% | 14.29% |
Operating Margin | -5.11% | -2.99% | -7.91% | -10.27% | -0.57% | -6.73% |
Pretax Margin | -36.26% | -31.55% | -34.06% | -11.16% | 0.93% | -37.84% |
Profit Margin | -37.26% | -32.58% | -32.76% | -10.95% | 2.46% | -35.40% |
FCF Margin | 7.81% | 8.04% | -2.54% | -5.03% | 5.75% | -11.48% |
| Fiscal Year | FY 2022 |
|---|---|
| Period Ending | Jan '23 Jan 1, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.030 |
Dividend Per Share Growth | - |
Dividend Yield | 0.85% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 159.37 | - |
Forward PE | - | 38.54 | 38.54 | 38.54 | 38.54 | 38.54 |
P/FCF Ratio | 75.25 | 75.06 | - | - | 68.10 | - |
PS Ratio | 5.88 | 6.03 | 5.03 | 3.71 | 3.92 | 4.37 |